Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).
about
Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome)Health-related quality of life in mucopolysaccharidosis: looking beyond biomedical issuesTen years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry.The factors affecting lipid profile in adult patients with MucopolysaccharidosisHeparin cofactor II-thrombin complex and dermatan sulphate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseasesOrthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey.Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome).Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and managementDiagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfallsDeep Genotyping of the IDS Gene in Colombian Patients with Hunter Syndrome.Prevention of lysosomal storage diseases and derivation of mutant stem cell lines by preimplantation genetic diagnosis.Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis.Mucopolysaccharidosis Type II and the G374sp Mutation.Development of a mnemonic screening tool for identifying subjects with Hunter syndrome.Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995-2012.Detection by Urinary GAG Testing of Mucopolysaccharidosis Type II in an At-Risk Spanish Population.Carotid intima-media thickness is increased in patients with mucopolysaccharidoses.Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA.Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.Management of the behavioural manifestations of Hunter syndrome.Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS).Successful noninvasive ventilation and enzyme replacement therapy in an adult patient with morbus hunterHunter syndrome follow-up after 1 year of enzyme-replacement therapyClinical outcomes in idursulfase-treated patients with mucopolysaccharidosis type II: 3-year data from the hunter outcome survey (HOS)Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter Syndrome).Enzyme Replacement Therapy in Mucopolysaccharidosis II Patients Under 1 Year of Age.IgE-mediated anaphylaxis and allergic reactions to idursulfase in patients with Hunter syndrome.Presentation and Treatments for Mucopolysaccharidosis Type II (MPS II; Hunter Syndrome).Whole-exome sequencing expands the phenotype of Hunter syndrome.Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype.A biochemical and physicochemical comparison of two recombinant enzymes used for enzyme replacement therapies of hunter syndrome.A comparison study of bioanalytical methods for characterization of anti-idursulfase antibodies.Retrospective analysis of the clinical manifestations and survival of Korean patients with mucopolysaccharidosis type II: emphasis on the cardiovascular complication and mortality cases.Improvement of CNS defects via continuous intrathecal enzyme replacement by osmotic pump in mucopolysaccharidosis type II mice.Clinical characteristics and surgical history of Taiwanese patients with mucopolysaccharidosis type II: data from the hunter outcome survey (HOS).Intrafamilial variability in the clinical manifestations of mucopolysaccharidosis type II: Data from the Hunter Outcome Survey (HOS).Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
P2860
Q24186164-A54E6704-BB85-4259-9010-86A3459C83DEQ24201176-81FDA46D-81F1-4BD8-AB04-E4BD46FF1C61Q24235224-DF719596-6F0E-4CD2-81CA-89D751564873Q26738901-C7214767-B4F7-41CB-B8A8-A1BC69468B50Q33630446-A8E0B865-3618-4810-BD3F-F8F7E03D0C79Q33716134-55B75798-B7A8-4EB9-89E0-95F2BCAAC0D8Q34714510-BD42150F-75F7-44D4-82CA-5BFA86D21A71Q35128899-D9259AEE-0F7E-4411-9B61-928F5D97907FQ35559229-BA23787E-2AD6-4BB0-BF61-B69DF57008B6Q35571515-61607849-FB10-480C-AD03-EFB88B511FA3Q35587435-49437553-8FA0-400B-841B-37BA027B26B5Q35836716-2FF9526B-7953-49CF-BB80-931D30466C4EQ35848742-F8696489-AB81-4389-85F3-79F740FDE062Q36520219-4985D14C-B1B8-493F-ACEF-D86E0DDD4A97Q36836581-D34D3430-0BFE-4B9F-90B0-85805AB437B3Q36883369-B4BBA009-00CC-4465-A3EA-B937DBACFCE6Q36983261-295DBC2B-9A9C-4210-BD99-92FBD36346C6Q37045386-1F236FE8-B058-46D8-B37F-C63B6E2E3E5CQ37127684-E7997057-EA41-47A0-8C62-EBD3FA86527FQ37584874-7C560331-6EDE-4CB7-B04C-E138E2E9421BQ37585553-D594E7ED-13C0-42B1-83DF-64A8D6C9D9EDQ38634722-F422501E-A176-40B1-A56A-1090D9D09FF8Q38696810-7107F25F-A1DF-4823-AF5A-25832F16A0DEQ40049935-B44106F1-12BC-43E2-BC5A-35881F12E77DQ41934288-E9775CFD-4A4C-40EF-8393-9A4674189369Q41973861-0FF73064-E8D0-4096-BA6A-E38C007CC3DDQ42281140-BB539109-3D81-4032-BA9C-356FAD8B48DDQ42477832-9969590F-27F1-4E77-98A2-C87240F6D898Q42967269-AD00E69C-EC9B-4271-B677-4B1CC829909AQ43530570-02F87D0F-7147-4A50-8F55-4751067911B4Q45874778-F002B91F-EE7E-47C2-9C16-38F53B4F45B8Q46399321-6865A6CC-CE4D-4C1F-AA1D-75BEC89E6781Q47364481-ADFF8CAD-D28C-4E7B-9A1F-7A3EF8D90AC9Q50457046-84823593-F432-41D4-A5A2-547DE036BB98Q52553010-4F0F1644-6CB2-4425-A187-270DEEBE61F5Q53397479-50EBAC27-6C99-4596-AA85-14402FD07689Q54202070-992A28D6-E38C-4462-9960-CABA094018B3Q55216367-3A9B26A1-B9DC-493E-B942-759ECB539336Q55442476-49FBDA4B-860F-4153-8F1C-D365C1DC4F42Q58696152-59A02AA2-2F31-49EE-B62E-878867DA13F2
P2860
Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Mortality and cause of death i ...... e Hunter Outcome Survey (HOS).
@ast
Mortality and cause of death i ...... e Hunter Outcome Survey (HOS).
@en
type
label
Mortality and cause of death i ...... e Hunter Outcome Survey (HOS).
@ast
Mortality and cause of death i ...... e Hunter Outcome Survey (HOS).
@en
prefLabel
Mortality and cause of death i ...... e Hunter Outcome Survey (HOS).
@ast
Mortality and cause of death i ...... e Hunter Outcome Survey (HOS).
@en
P2093
P1476
Mortality and cause of death i ...... e Hunter Outcome Survey (HOS).
@en
P2093
C Hendriksz
HOS Investigators
J E Wraith
J T Clarke
R Giugliani
R Tincheva
P2888
P304
P356
10.1007/S10545-009-1119-7
P577
2009-07-14T00:00:00Z
P6179
1034705175